Xencor shares rise on data from XmAb819 trial
Xencor released updated results from a Phase 1 study on its XmAb819 bispecific antibody for kidney cancer. Positive data led to a strong market reaction.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed